PUBLISHER: DelveInsight | PRODUCT CODE: 1246744
PUBLISHER: DelveInsight | PRODUCT CODE: 1246744
"Bimekizumab Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about Bimekizumab for Hidradenitis Suppurativa (HS) in the 7MM. A detailed picture of the Bimekizumab for Hidradenitis Suppurativa in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the UK, and Japan, for the study period 2019-2032 is provided in this report along with a detailed description of the Bimekizumab for Hidradenitis Suppurativa. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the Bimekizumab market forecast, analysis for Hidradenitis Suppurativa in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Hidradenitis Suppurativa.
BIMZELX (bimekizumab) is the first humanized monoclonal IgG1 antibody that potently and selectively neutralizes both IL-17A and IL-17F, two key cytokines driving inflammatory processes. IL-17A and IL-17F are the most closely related members of the IL-17 family of cytokines, and they are both co-expressed at sites of inflammation and have overlapping pro-inflammatory functions. Both IL-17A and IL-17F can independently cooperate with other inflammatory mediators to drive chronic inflammation and tissue destruction. UCB is investigating bimekizumab in HS and expects to submit global regulatory applications for bimekizumab in moderate-to-severe HS starting in Q3 2023.
In March 2023, UCB announced detailed positive results from two Phase III studies (BE HEARD I and BE HEARD II) evaluating the efficacy and safety of bimekizumab in the treatment of adults with moderate-to-severe hidradenitis suppurativa (HS). Data from the two studies showed that bimekizumab achieved statistically significant and consistent clinically meaningful improvements over the placebo in the signs and symptoms of HS at week 16, which were maintained to week 48. Clinical responses with bimekizumab were observed from the first dose, with some patients achieving HiSCR50 at week four.
The report is built using data and information sourced primarily from internal databases, primary and secondary research, and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals, and access to available databases.
This report provides a detailed market assessment of Bimekizumab in Hidradenitis Suppurativa in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.
The report provides the clinical trials information of Bimekizumab in Hidradenitis Suppurativa covering trial interventions, trial conditions, trial status, start and completion dates.